A Phase IIb, Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AZD0780 in Participants With Dyslipidemia
Latest Information Update: 04 Apr 2025
At a glance
- Drugs AZD 0780 (Primary)
- Indications Dyslipidaemias
- Focus Therapeutic Use
- Acronyms PURSUIT
- Sponsors AstraZeneca
Most Recent Events
- 31 Mar 2025 According to an AstraZeneca Media Release, data from this study presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo in Chicago, Illinois, US and published simultaneously in JACC.
- 31 Mar 2025 Results presented in an AstraZeneca Media Release.
- 08 Oct 2024 Status changed from active, no longer recruiting to completed.